British Society for Antimicrobial Chemotherapy

The British Society for Antimicrobial Chemotherapy, founded in 1971 by clinicians and scientists alarmed by infectious diseases and rising drug-resistant infections, pursues a mission of fostering a safer world through responsible antimicrobial use, advancing health outcomes, and championing scientific excellence. Guided by values of rigorous science, multidisciplinary collaboration, education, transparency, and public benefit, their grantmaking philosophy emphasizes evidence-based innovation, knowledge dissemination, and global partnerships to combat antimicrobial resistance (AMR) as a critical public health threat, believing systemic change arises from connecting researchers, clinicians, policymakers, and industry to drive stewardship, surveillance, and informed practice.

They prioritize antimicrobial stewardship interventions, infection prevention strategies, and research advancing microbial surveillance, prescribing pattern analysis, and novel antimicrobial therapies, funding projects for clinicians including microbiologists, pharmacists, surgeons, veterinarians, and nurses tackling hospital-acquired infections, community-onset resistance, and global AMR hotspots. Supported activities encompass professional education via conferences, e-learning modules, mentorship programs, and public engagement events raising awareness of responsible antibiotic use; development of evidence-based guidelines, management toolkits, and stewardship accreditation schemes for healthcare institutions; peer-reviewed research dissemination through leading journals; open-access bioresources of microbial isolates and surveillance data; and cross-sector collaborations shaping policy on infection control, outbreak response, and resistance mitigation, with emphasis on preventative approaches, scalable stewardship models, and international knowledge sharing to empower health professionals and institutions in low-resource settings.

They exclude funding for non-AMR activities, unrelated scientific fields, or projects lacking evidence-based rigor and public health alignment, prioritizing global infection specialists, multidisciplinary teams, and charities advancing microbial science advocacy over individual treatments or commercial ventures. Distinctive for decades-long leadership in AMR surveillance, journal publishing preeminence, stewardship accreditation expertise, and convening diverse professionals from 135 nations, they favor innovative, transparent initiatives with conflict-of-interest safeguards, international reach, and measurable impact on resistance trends through education, research, and policy influence.